SAN DIEGO--(BUSINESS WIRE)--Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting its Cloudbreak™ immunotherapy discovery platform and new antiviral program at the upcoming World Antimicrobial Resistance (AMR) Congress taking place October 25-26, 2018 in Washington, DC. The presentation, titled “Immunobiotics: Cloudbreak Antibody Drug Conjugates (ADC) as countermeasures against multi-drug resistant bacterial infections," is scheduled for 11:10 a.m. Eastern Time on Friday, October 26.
As the leading conference on antimicrobial resistance, the World Antimicrobial Resistance Congress convenes over 400 stakeholders to discuss critical challenges and opportunities to advance antibiotic and diagnostics development, improve antimicrobial stewardship practice and incentivize funding and partnering to bring innovation to patients and the healthcare system in need. More information about the 2018 World Antimicrobial Congress can be found at: http://www.terrapinn.com/conference/antimicrobial-resistance-congress-usa/index.stm
The Cloudbreak immunotherapy platform is a fundamentally new approach for the treatment of infectious disease that, in a single molecule, pairs potent antimicrobials with agents that redirect the immune system to destroy fungal, bacterial and viral pathogens. Cidara is initially developing Cloudbreak candidates for the treatment and prevention of serious multi-drug resistant (MDR) Gram-negative bacterial infections and viral infections. Different from traditional antibiotics or antivirals, the Cloudbreak ADCs physically link the pathogen and the immune component to eradicate or prevent pathogens via dual killing mechanisms.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial in the treatment of candidemia and invasive candidiasis and plans to initiate a second Phase 3 trial in the prophylaxis of invasive fungal infections. Rezafungin has improved pharmacokinetics compared to existing echinocandins and the potential for expanded utility across patient settings. It is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. Cidara also is leveraging its novel Cloudbreak™ platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the first immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the potential for the Cloudbreak immunotherapy platform to treat and prevent serious multi-drug resistant Gram-negative bacterial infections and viral infections and to fundamentally change the treatment of infectious diseases. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Cidara’s plans to develop and commercialize its product candidates; Cidara’s ability to obtain additional financing; Cidara’s ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Cidara’s Form 10-Q most recently filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.